IIM
LCTX icon

INTECH Investment Management’s Lineage Cell Therapeutics LCTX Stock Holding History

INTECH Investment Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.2K Buy
+37,569
New +$51.9K ﹤0.01% 2054
2025
Q2 		– Sell
-50,922
Closed -$23K – 2573
2025
Q1 		$23K Buy
+50,922
New +$29.9K ﹤0.01% 2496

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DC
Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
RA
Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

INTECH Investment Management's LCTX Position: Q2 2026 in Review

INTECH Investment Management opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 37,569 shares worth $49.2K. The stake represents ﹤0.01% of the portfolio and ranks #2054 among its holdings. This is a return to the name: INTECH Investment Management previously reported a position in LCTX as recently as Q1 2025.

INTECH Investment Management first reported a position in LCTX in Q1 2025 and has held it in 2 quarters since. 132 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

  • INTECH Investment Management held 37,569 shares of Lineage Cell Therapeutics worth $49.2K as of Q2 2026.
  • Lineage Cell Therapeutics was a new INTECH Investment Management position in Q2 2026.
  • Lineage Cell Therapeutics made up ﹤0.01% of INTECH Investment Management's portfolio in Q2 2026, its #2054 holding.
  • INTECH Investment Management first reported a position in Lineage Cell Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 132 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on INTECH Investment Management's 13F filing for Q2 2026, filed 10 Aug 2026.